Lytix Biopharma AS is a privately-owned pharmaceutical company developing novel antimicrobial peptide-based drugs for the treatment of resistant bacterial and fungal infections, as well as first-in-class oncology treatments.

Lytix Biopharma AS is pleased to announce that we have expanded our teams of drug development professionals.

Berit Nicolaisen, MSc, has broad experience from the pharmaceutical industry, and has previously been engaged at PhotoCure ASA. In Lytix Biopharma she holds a position as Project Manager of the oncology development team.

Ali Areffard, PhD, who has comprehensive experience within immunology and tumor biology from the Norwegian Radium Hospital, is engaged as Project Manager of the oncology research team.

Mette Husbyn, PhD, who will join the teams shortly, will be responsible for the CMC department. She has wide experience within the CMC value chain including peptide chemistry, and is coming from a position as Department Manager in GE Healthcare.

Lytix Biopharma is very much looking forward to taking advantage of the experience of our new colleagues and welcome them to the company. 

We now have job openings for exceptional employees within the following manager positions:

• Regualtory Affairs/Quality Assurance
• Clinical Study Manager
• IPR Manager

For more information please click on the position of your interest. 

Se more posters from 51st Interscience Conference on Antimicrobial Agents and Chemotherapy 2011 in Chicago here